Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
J&J's IL-23 drug defeats Sotyktu in phase 3 psoriasis trial
After being touted as a rival to BMS’ reigning psoriasis med Sotyktu for months, J&J’s IL-23 drug looks like it has a shot at taking the crown.
James Waldron
Sep 17, 2025 9:45am
Regeneron's ultrarare disease phase 3 hits, teeing up filings
Sep 17, 2025 9:31am
Sanofi's R&D chief 'pretty pragmatic' about clinical setbacks
Sep 17, 2025 8:01am
Roivant reports phase 3 autoimmune win for ex-Pfizer asset
Sep 17, 2025 7:00am
Apollo $15M bet on IL-18 antibody pays off with ph. 2 eczema win
Sep 16, 2025 9:50am
Areteia posts ph. 3 asthma win for oral rival to biologic drugs
Sep 16, 2025 9:20am
